PUBLISHER: Grand View Research | PRODUCT CODE: 1701238
PUBLISHER: Grand View Research | PRODUCT CODE: 1701238
The global lab-on-a-chip market size is expected to reach USD 11.45 billion by 2030 and is expected to grow at a CAGR of 9.76% from 2025 to 2030 according to a new report by Grand View Research, Inc. The market is driven by rising investments in healthcare R&D, integration of AI in diagnostics, and government initiatives supporting personalized medicine and decentralized testing.
The lab-on-a-chip market is experiencing significant growth due to advancements in microfluidics technology, which has improved the precision and efficiency of diagnostic processes. In addition, the integration of lab-on-a-chip devices in clinical and research laboratories has streamlined workflows, further reducing the time required for complex analyses. The demand for high-throughput screening in the pharmaceutical and biotechnology industries has also expanded the applications of lab-on-a-chip technology, enabling faster drug discovery and personalized treatment approaches.
Furthermore, the rising adoption of telemedicine and remote patient monitoring has increased the need for portable diagnostic solutions, which has placed lab-on-a-chip as an important component in decentralized healthcare systems. The development of cost-effective manufacturing techniques, including 3D printing and nanofabrication, has enhanced the scalability of lab-on-a-chip production, making these devices more accessible. Moreover, increasing government funding and private investments in healthcare innovation have further accelerated research and commercialization of lab-on-a-chip technologies.
Key market players are adopting various strategies to enhance the effectiveness and reliability of Lab-on-a-Chip technologies by integrating advanced microfluidics, AI-driven analytics, and biomimetic systems. Companies are focusing on improving drug testing accuracy, organ-on-chip models, and point-of-care diagnostics to meet the growing demand for personalized medicine and decentralized healthcare. In September 2024, Emulate, Inc. announced the launch of Chip-R1 Rigid Chip, designed to minimize drug absorption and enhance biological modeling. This innovation addresses the challenge of drug compound loss during in vitro testing, thereby improving the accuracy of pharmacokinetic and toxicological assessments.